INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 273 filers reported holding INTRA CELLULAR THERAPIES INC in Q1 2023. The put-call ratio across all filers is 0.28 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $74,619,758 | -30.5% | 1,432,516 | -15.5% | 0.33% | -28.6% |
| Q2 2023 | $107,378,563 | +77.6% | 1,695,808 | +51.9% | 0.46% | +54.2% |
| Q1 2023 | $60,445,696 | -34.0% | 1,116,264 | -35.5% | 0.30% | -46.9% |
| Q4 2022 | $91,609,442 | +23.7% | 1,731,093 | +8.8% | 0.56% | +18.2% |
| Q3 2022 | $74,047,000 | -20.3% | 1,591,383 | -2.2% | 0.47% | -15.7% |
| Q2 2022 | $92,892,000 | +110.1% | 1,627,408 | +125.2% | 0.56% | +143.9% |
| Q1 2022 | $44,223,000 | – | 722,724 | – | 0.23% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ally Bridge Group (NY) LLC | 175,000 | $9,115,750 | 10.70% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 317,856 | $16,547,583 | 5.57% |
| Deep Track Capital, LP | 2,600,000 | $135,434,000 | 5.23% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,369,849 | $71,355,434 | 3.86% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 208,730 | $10,872,746 | 3.30% |
| DCF Advisers, LLC | 107,157 | $5,581,808 | 3.04% |
| Bellevue Group AG | 3,170,250 | $165,138,323 | 2.66% |
| Vahanian & Associates Financial Planning Inc. | 15,217 | $792,654 | 2.55% |
| Iron Triangle Partners LP | 330,549 | $17,218,297 | 2.52% |
| TANG CAPITAL MANAGEMENT LLC | 300,000 | $15,627,000 | 2.20% |